Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma
- Author
- Nora Sundahl, Teofila Seremet, Jo Van Dorpe (UGent) , Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez (UGent) , Vibeke Kruse (UGent) and Piet Ost (UGent)
- Organization
- Keywords
- Cancer Research, Oncology, Radiation, Radiology Nuclear Medicine and imaging, SOLID TUMORS, RADIOTHERAPY, IPILIMUMAB, PEMBROLIZUMAB, COMBINATION, GUIDELINES, ANTI-PD-1, SURVIVAL, IMMUNITY, CANCER
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 637.77 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8667707
- MLA
- Sundahl, Nora, et al. “Phase 2 Trial of Nivolumab Combined with Stereotactic Body Radiation Therapy in Patients with Metastatic or Locally Advanced Inoperable Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 104, no. 4, 2019, pp. 828–35, doi:10.1016/j.ijrobp.2019.03.041.
- APA
- Sundahl, N., Seremet, T., Van Dorpe, J., Neyns, B., Ferdinande, L., Meireson, A., … Ost, P. (2019). Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 104(4), 828–835. https://doi.org/10.1016/j.ijrobp.2019.03.041
- Chicago author-date
- Sundahl, Nora, Teofila Seremet, Jo Van Dorpe, Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez, Vibeke Kruse, and Piet Ost. 2019. “Phase 2 Trial of Nivolumab Combined with Stereotactic Body Radiation Therapy in Patients with Metastatic or Locally Advanced Inoperable Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 104 (4): 828–35. https://doi.org/10.1016/j.ijrobp.2019.03.041.
- Chicago author-date (all authors)
- Sundahl, Nora, Teofila Seremet, Jo Van Dorpe, Bart Neyns, Liesbeth Ferdinande, Annabel Meireson, Lieve Brochez, Vibeke Kruse, and Piet Ost. 2019. “Phase 2 Trial of Nivolumab Combined with Stereotactic Body Radiation Therapy in Patients with Metastatic or Locally Advanced Inoperable Melanoma.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 104 (4): 828–835. doi:10.1016/j.ijrobp.2019.03.041.
- Vancouver
- 1.Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A, et al. Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2019;104(4):828–35.
- IEEE
- [1]N. Sundahl et al., “Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma,” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 104, no. 4, pp. 828–835, 2019.
@article{8667707,
author = {{Sundahl, Nora and Seremet, Teofila and Van Dorpe, Jo and Neyns, Bart and Ferdinande, Liesbeth and Meireson, Annabel and Brochez, Lieve and Kruse, Vibeke and Ost, Piet}},
issn = {{0360-3016}},
journal = {{INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS}},
keywords = {{Cancer Research,Oncology,Radiation,Radiology Nuclear Medicine and imaging,SOLID TUMORS,RADIOTHERAPY,IPILIMUMAB,PEMBROLIZUMAB,COMBINATION,GUIDELINES,ANTI-PD-1,SURVIVAL,IMMUNITY,CANCER}},
language = {{eng}},
number = {{4}},
pages = {{828--835}},
title = {{Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma}},
url = {{http://doi.org/10.1016/j.ijrobp.2019.03.041}},
volume = {{104}},
year = {{2019}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: